Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV4 | Q9HBA0 | 3/20 | 0.42 |
| ▸ | KHK | P50053 | 1/20 | 0.36 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.31 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.31 |
| ▸ | SNCA | P37840 | 1/20 | 0.31 |
| ▸ | DPP4 | P27487 | 1/20 | 0.31 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.30 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL363766 | 0.85 | TRPV4 (0.50) | TRPV4KHKCYP11B1CYP11B2ADRB2 | |
| SCHEMBL1585046 | 0.84 | SNCA (0.35) | TRPV4SNCA | |
| SCHEMBL22188019 | 0.78 | TRPV4 (0.42) | TRPV4KHKCYP11B1CYP11B2 | |
| SCHEMBL16061907 | 0.78 | TRPV4 (0.42) | TRPV4KHKCYP11B1CYP11B2ADRB2 | |
| SCHEMBL29518514 | 0.78 | TRPV4 (0.42) | TRPV4KHKCYP11B1CYP11B2ADRB2 | |
| SCHEMBL4826854 | 0.75 | DPP4 (0.39) | DPP4 | |
| SCHEMBL2783854 | 0.75 | TRPV4 (0.56) | TRPV4KHKCYP11B1CYP11B2ALDH1A1 | |
| SCHEMBL30149683 | 0.75 | DPP4 (0.39) | DPP4 | |
| SCHEMBL305457 | 0.75 | MAOA (0.41) | TRPV4CYP11B1CYP11B2DPP4 | |
| SCHEMBL534825 | 0.75 | MAOA (0.38) | TRPV4CYP11B1CYP11B2SNCADPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110325531-B | Benzenesulfonamides and their use as therapeutic agents | 泽农医药公司 | 2022-05-27 | — | — | CN | disclosed |
| EP-3305787-B1 | XANTHINE DERIVATIVE | JIANGSU TASLY DIYI PHARMACEUTICAL CO LTD (CN) | 2022-02-16 | — | — | EP | disclosed |
| US-11174268-B2 | Benzenesulfonamide compouds and their use as therapeutic agents | XENON PHARMACEUTICALS INC. (CA) | 2021-11-16 | — | — | US | disclosed |
| US-20210171537-A1 | BENZENESULFONAMIDE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2021-06-10 | — | — | US | disclosed |
| EP-3551626-A1 | BENZENESULFONAMIDE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | Xenon Pharmaceuticals Inc. (CA) | 2019-10-16 | — | — | EP | disclosed |
| CN-110325531-A | Benzsulfamide and its purposes as therapeutic agent | 泽农医药公司 | 2019-10-11 | — | — | CN | disclosed |
| WO-2018106284-A1 | BENZENESULFONAMIDE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2018-06-14 | — | — | WO | disclosed |
| US-20180162860-A1 | XANTHINE DERIVATIVE | JIANGSU TASLY DIYI PHARMACEUTICAL CO., LTD. (CN) | 2018-06-14 | — | — | US | disclosed |
| US-20180162868-A1 | BENZENESULFONAMIDE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2018-06-14 | — | — | US | disclosed |
| EP-3305787-A1 | XANTHINE DERIVATIVE | Jiangsu Tasly Diyi Pharmaceutical Co., Ltd. (CN) | 2018-04-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180162860-A1 | XANTHINE DERIVATIVE | XDH, CXCR1, CBR1 | TRPV4 4654/4885KHK 1078/4885CYP11B1 15/4885 |
| US-11174268-B2 | Benzenesulfonamide compouds and their use as therapeutic agents | KCND2, SCN1A, CACNA1D | TRPV4 32/4885KHK 2145/4885CYP11B1 1003/4885 |
| US-20210171537-A1 | BENZENESULFONAMIDE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | SCN1A, SCN1B, SCN2B | TRPV4 37/4885KHK 2080/4885CYP11B1 987/4885 |
| US-20180162868-A1 | BENZENESULFONAMIDE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | SCN1A, SCN1B, SCN2B | TRPV4 37/4885KHK 2080/4885CYP11B1 987/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.